Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05160506 · ClinicalTrials.gov registry record · Phase 2
Corticosteroids to Treat Pancreatitis
A Phase 2 study of Pancreatitis and Pancreatitis, Acute, sponsored by Beth Israel Deaconess Medical Center.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 86
- Enrollment target
- 1
- Study location
NCT05160506: Recruiting Phase 2 study of Pancreatitis and Pancreatitis, Acute, sponsored by Beth Israel Deaconess Medical Center.
NCT05160506 is a Phase 2 study of Pancreatitis and Pancreatitis, Acute that is actively recruiting participants, run by Beth Israel Deaconess Medical Center. The registered enrollment target is 86 participants, below the 617-participant average among 17 other Pancreatitis trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05160506, a Phase 2 study of Pancreatitis and Pancreatitis, Acute, is actively recruiting participants, sponsored by Beth Israel Deaconess Medical Center.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 86 participants
- Enrollment target
- 1
- Study location
Study Summary
This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammation in the body drives the progression of pancreatitis, giving a short course of intravenous hydrocortisone may mitigate disease progression and improve clinical outcomes in patients with severe acute pancreatitis.
Primary Outcome
Change in Sequential Organ failure Assessment (SOFA) Score over 72 hours
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Hydrocortisone
Study Locations (1)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 86 participants |
| Start Date | 2022-03-06 |
| Est. Completion | 2027-04 |
| Phase | Phase 2 |
What NCT05160506 shows while recruiting
NCT05160506 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 86 participants, a relatively small participant target, below the 617-participant average among 17 other Pancreatitis trials with a reported enrollment target (86% lower).
The record links to 4 conditions, with Pancreatitis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05160506 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT05160506 about?
NCT05160506 is a clinical study titled "Corticosteroids to Treat Pancreatitis". This research is being done to determine if the administration of a short course of intravenous hydrocortisone, an anti-inflammatory medication, to patients with severe acute pancreatitis will improve their clinical outcomes and decrease the length of hospitalization. We think that because inflammat...
What is the current status of trial NCT05160506?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 86 participants. The study started on 2022-03-06. Estimated completion is 2027-04.
What conditions does trial NCT05160506 study?
This clinical trial studies the following conditions: Pancreatitis, Pancreatitis, Acute, Corticosteroid, Hydrocortisone.
What interventions are being tested in trial NCT05160506?
The interventions under investigation include: Placebo (DRUG), Hydrocortisone (DRUG).
Who is sponsoring clinical trial NCT05160506?
This trial is sponsored by Beth Israel Deaconess Medical Center, which has 488 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05160506 being conducted?
This trial has 1 study location across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pancreatitis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05160506's enrollment target sits among peer trials
86 11th of 17 higher than 7 of 17 other Pancreatitis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pancreatitis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Prospective Evaluation of Chronic Pancreatitis for Epidemiologic and Translational Studies
RECRUITING
-
Building and Sustaining Exercise Habits for Adults With Type 1 Diabetes
RECRUITING · NA
-
Scrambler Therapy in Chronic Pancreatitis
RECRUITING · NA
-
PROMs After Pancreatectomy
RECRUITING
-
Pancreas Registry and High Risk Registry
RECRUITING
-
A Study of Blood Based Biomarkers for Pancreas Adenocarcinoma
RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01639508 · 86 participants · Phase 2
Cabozantinib in Patients With RET Fusion-Positive Advanced Non-Small Cell Lung Cancer and Those With Other Genotypes: ROS1 or NTRK Fusions or Increased MET or AXL Activity
- NCT03519269 · 86 participants · NA
Navio Robotic Versus Conventional Total Knee Arthroplasty
- NCT04132999 · 86 participants · NA
PAP for Children With DS and OSAS
- NCT04545957 · 86 participants · NA
Jump: MR Simulation For Radiation Therapy Master Protocol
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI